The Role of Vascular Endothelial Growth Factor (VEGF) as A Potential Therapy of Psoriasis Vulgaris: A Literature Review
Keywords:Vascular endothelial growth factor (VEGF),, psoriasis vulgaris, therapy, angiogenesis
AbstractPsoriasis management remains a challenge due to the difficulty of achieving therapeutic targets which are influenced by factors such as varying degrees of psoriasis, lack of therapeutic efficacy, and side effects of therapy. Various efforts are being made to find the best and most effective therapy. Pathogenesis of psoriasis is influenced by T cells, skin vascular disorders also play an important role. Angiogenesis in psoriasis is mediated by vascular endothelial growth factor (VEGF), angiopoietin, tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), and interleukin-17 (IL-17). VEGFA inhibitors still have not received approval in psoriasis therapy, however two case reports of psoriasis patients with 40% and 50% lesion areas experienced significant improvement after bevacizumab administration. The angiogenic factor of VEGF acts as an important biomarker in psoriasis vulgaris and is histopathologically found in keratinocytes. The standard therapy of psoriasis vulgaris has been known to have good efficacies, but both long-term efficacy and treatment failures often occur, patients could not prevent relapse and serious side effects. Therapeutic agents that target VEGF directly including anti-VEGF monoclonal antibodies, VEGF receptor antagonist fusion proteins, receptor tyrosine kinase inhibitors, NVP-BAW2881, and traditional therapeutic agent PSORI-CM02. These therapies are quite promising, though there are various side effects associated with systemic administration of VEGF inhibitors, including proteinuria, hypertension and impaired wound healing. Thus, the development of anti-VEGF as a therapy in the management of psoriasis requires careful evaluation especially to minimize the toxicity of the treatment.
Lee H, Hong Y, Kim M. Angiogenesis in Chronic Inflammatory Skin Disorders. Int J Mol ecular Sci 2021; 22: 1–15.
Benhadou F, Glitzner E, Brisebarre A, et al. Epidermal autonomous VEGFA/Flt1/Nrp1 functions mediate psoriasis-like disease. Sci Adv 2023; 6: eaax5849.
Murray S, Crowley J, Gooderham MJ, et al. Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study. J Psoriasis Psoriatic Arthritis 2021; 7: 35–43.
Luengas-Martinez A, Hardman-Smart J, Paus R, et al. Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis. Exp Dermatol 2020; 29: 687–698.
Gerkowicz A, Socha M, Pietrzak A, et al. The role of VEGF in psoriasis: an update. Acta Angiol 2018; 24: 134–140.
Brandon A, Mufti A, Gary Sibbald R. Diagnosis and Management of Cutaneous Psoriasis: A Review. Adv Skin Wound Care; 32, https://journals.lww.com/aswcjournal/Fulltext/2019/02000/Diagnosis_and_Management_of_Cutaneous_Psoriasis__A.3.aspx (2019).
Yunita I, Anggraeni S. Secukinumab Therapy in Psoriasis Management. Berk Ilmu Kesehat Kulit dan Kelamin2 2022; 34: 59–65.
Segar D, Praharsini I, Indira I. Prevalence and clinical manifestations of patients with psoriasis in RSUP Sanglah from 2017 to 2018. Intisari Sains Medis 2019; 10: 840–844.
Johnson MAN, Armstrong AW. Clinical and Histologic Diagnostic Guidelines for Psoriasis: A Critical Review. Clin Rev Allergy Immunol 2013; 44: 166–172.
Guerard S, Pouliot R. The Role of Angiogenesis in the Pathogenesis of Psoriasis: Mechanisms and Clinical Implications. J Clin Exp Dermatology Res 2014; 4: 1–7.
Chen W, Wu L, Zhu W, et al. The polymorphisms of growth factor genes (VEGFA & EGF) were associated with response to acitretin in psoriasis. Per Med 2018; 15: 181–188.
Crawshaw AA, Griffiths CEM, Young HS. Investigational VEGF antagonists for psoriasis. Expert Opin Investig Drugs 2012; 21: 33–43.
Manuputty AG, Murtiastutik D, Sawitri S, et al. The Comparison of Candida spp. Colonization on Psoriasis Vulgaris Patient and Control. Berk Ilmu Kesehat Kulit dan Kelamin 2021; 33: 40–47.
Výbohová D, Adamicová K, Mellová Y, et al. Microvascular changes in relation to inflammation and epidermal hyperplasia in chronic cutaneous lesions of psoriasis vulgaris. Histol Histopathol 2017; 32: 461–70.
Sneha C, Govind B, Mounika C, et al. Assessment of Quality of Life and Effectiveness of Different Therapies in the Management of Psoriasis at Tertiary Care Hospital in Hyderabad. World J Pharm Res 2018; 7: 1049–68.
Coimbra S, Oliveira H, Figueiredo A, et al. Psoriasis: Epidemiology, Clinical and Histological Features, Triggering Factors, Assessment of Severity and Psychosocial Aspects. In: O’Daly J (ed) Psoriasis - A Systematic Disease. London: IntechOpen, 2012, pp. 69–88.
Anupama Y, Patil S. A retrospective clinicohistopathological study of psoriasis. IP Indian J Clin Exp Dermatology 2020; 6: 222–226.
Morar I, Tabăran F, Mocan T, et al. Immunohistochemical study of psoriatic plaques and perilesional skin in psoriasis vulgaris patients: A pilot study. Exp Ther Med 2019; 18: 888–894.
El-Sherbini S, Salama A, Rashed L, et al. Association between IL-37 and VEGF Gene Expression in Psoriasis Pathogenesis in Egyptian Population. J Biosci Med 2022; 10: 136–149.
Vide J, Magina S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. An Bras Dermatol 2017; 92: 668–674.
Sutaria N, Au SC. Failure rates and survival times of systemic and biologic therapies in treating psoriasis: a retrospective study. J Dermatolog Treat 2021; 32: 617–620.
Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther 2015; 28: 390–403.
Svedbom A, Dalén J, Mamolo C, et al. Treatment patterns with topicals, traditional systemics and biologics in psoriasis - A Swedish database analysis. J Eur Acad Dermatology Venereol 2015; 29: 215–223.
Bae O-N, Noh M, Chun Y-J, et al. Keratinocytic Vascular Endothelial Growth Factor as a Novel Biomarker for Pathological Skin Condition. Biomol Ther (Seoul) 2015; 23: 12–18.
Lal N, Puri K, Rodrigues B. Vascular Endothelial Growth Factor B and Its Signaling . Frontiers in Cardiovascular Medicine ; 5, https://www.frontiersin.org/articles/10.3389/fcvm.2018.00039 (2018).
Malecic N, Young HS. Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis. Expert Opin Investig Drugs 2016; 25: 455–462.
Guo D, Murdoch CE, Liu T, et al. Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review . Frontiers in Pharmacology ; 9, https://www.frontiersin.org/articles/10.3389/fphar.2018.00428 (2018).
Waworuntu G, Tanjung C, Mahadi I. Profil Kadar Vascular Endothelial Growth Factor (VEGF) Serum Berdasarkan Karakteristik Pasien Psoriasis Vulgaris di RSUP H. Adam Malik Medan. Media Dermato-Venereologica Indones 2017; 44: 8–14.
Sankar L, Arumugam D, Boj S, et al. Expression of angiogenic factors in psoriasis vulgaris. J Clin Diagnostic Res 2017; 11: EC23–27.
Singh M, Rani C, Nath D, et al. Role of Vascular Endothelial Growth Factor and Survivan Expression in Pathogenesis of Psoriasis. East African Sch J Med Sci 2009; 4421: 712–718.
Luengas-Martinez A, Hardman-Smart J, Rutkowski D, et al. Vascular Endothelial Growth Factor Blockade Induces Dermal Endothelial Cell Apoptosis in a Clinically Relevant Skin Organ Culture Model. Skin Pharmacol Physiol 2020; 33: 110–118.
Weidemann AK, Crawshaw AA, Byrne E, et al. Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clin Cosmet Investig Dermatol 2013; 6: 233–244.
Lu Y, Yang Y, Zhang J, et al. Anti-Angiogenic Efficacy of PSORI-CM02 and the Associated Mechanism in Psoriasis In Vitro and In Vivo . Frontiers in Immunology ; 12, https://www.frontiersin.org/articles/10.3389/fimmu.2021.649591 (2021).